Clinical trial
Extension Study to Evaluate the Safety and Efficacy of Luspatercept in…
NCT02268409 · Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA, Industry · Completed
Key facts
| NCT number | NCT02268409 |
|---|---|
| Title | Extension Study to Evaluate the Safety and Efficacy of Luspatercept in Participants With β-Thalassemia Previously Enrolled in A536-04 (A536-06/MK-6143-004) |
| Official title | An Open-Label Extension Study To Evaluate The Long-Term Effects Of ACE-536 In Patients With β-Thalassemia Previously Enrolled In Study A536-04 |
| Lead sponsor | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | β-Thalassemia |
| Intervention type | Drug |
| Interventions | luspatercept |
| Enrollment | 51 |
| Start date | Oct 20, 2014 |
| Primary completion | Jun 18, 2020 |
| Completion | Jun 18, 2020 |
| First posted | Oct 20, 2014 |
| Last update posted | Jul 18, 2024 |
| Countries | Greece, Italy |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: